Literature DB >> 2237444

Regulation of gene expression with double-stranded phosphorothioate oligonucleotides.

A Bielinska1, R A Shivdasani, L Q Zhang, G J Nabel.   

Abstract

Alteration of gene transcription by inhibition of specific transcriptional regulatory proteins is necessary for determining how these factors participate in cellular differentiation. The functions of these proteins can be antagonized by several methods, each with specific limitations. Inhibition of sequence-specific DNA-binding proteins was achieved with double-stranded (ds) phosphorothioate oligonucleotides that contained octamer or kappa B consensus sequences. The phosphorothioate oligonucleotides specifically bound either octamer transcription factor or nuclear factor (NF)-kappa B. The modified oligonucleotides accumulated in cells more effectively than standard ds oligonucleotides and modulated gene expression in a specific manner. Octamer-dependent activation of a reporter plasmid or NF-kappa B-dependent activation of the human immunodeficiency virus (HIV) enhancer was inhibited when the appropriate phosphorothioate oligonucleotide was added to a transiently transfected B cell line. Addition of phosphorothioate oligonucleotides that contained the octamer consensus to Jurkat T leukemia cells inhibited interleukin-2 (IL-2) secretion to a degree similar to that observed with a mutated octamer site in the IL-2 enhancer. The ds phosphorothioate oligonucleotides probably compete for binding of specific transcription factors and may provide anti-viral, immunosuppressive, or other therapeutic effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2237444     DOI: 10.1126/science.2237444

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  78 in total

1.  E2F is required to prevent inappropriate S-phase entry of mammalian cells.

Authors:  S He; B L Cook; B E Deverman; U Weihe; F Zhang; V Prachand; J Zheng; S J Weintraub
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

2.  A role for NF-kappaB-dependent gene transactivation in sunburn.

Authors:  K Abeyama; W Eng; J V Jester; A A Vink; D Edelbaum; C J Cockerell; P R Bergstresser; A Takashima
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 3.  One path to cell death in the nervous system.

Authors:  J Glasgow; R Perez-Polo
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

4.  Series introduction: emerging clinical applications of nucleic acids

Authors: 
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 5.  Therapeutic applications of transcription factor decoy oligonucleotides.

Authors:  M J Mann; V J Dzau
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

6.  The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts.

Authors:  B C Chu; L E Orgel
Journal:  Nucleic Acids Res       Date:  1992-11-11       Impact factor: 16.971

7.  NF-kappaB decoy oligonucleotides suppress RANTES expression and monocyte chemotactic activity via NF-kappaB inactivation in stromal cells of ectopic endometrium.

Authors:  Wang Xiu-li; Han Su-ping; Dai Hui-hua; You Zhi-xue; Fu Shi-long; Lu Pin-hong
Journal:  J Clin Immunol       Date:  2009-01-27       Impact factor: 8.317

8.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

9.  Modulation of oligonucleotide duplex and triplex stability via hydrophobic interactions.

Authors:  S M Gryaznov; D H Lloyd
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

Review 10.  Aptamers and the next generation of diagnostic reagents.

Authors:  Varatharasa Thiviyanathan; David G Gorenstein
Journal:  Proteomics Clin Appl       Date:  2012-12       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.